TFF Pharmaceuticals, Inc. (TFFP)
Largest Insider Buys in Sector
TFFP Stock Price History Chart
TFFP Stock Performance
About TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
Insider Activity of TFF Pharmaceuticals, Inc.
Over the last 12 months, insiders at TFF Pharmaceuticals, Inc. have bought $205,000 and sold $94,433 worth of TFF Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at TFF Pharmaceuticals, Inc. have bought $398,566 and sold $11.55M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Weisman Harlan F (President and CEO) — $300,000. Mikhak Zamaneh (Chief Medical Officer) — $30,000. Roberts Brandi (director) — $15,000.
The last purchase of 600,000 shares for transaction amount of $150,000 was made by Weisman Harlan F (President and CEO) on 2023‑08‑15.
List of Insider Buy and Sell Transactions, TFF Pharmaceuticals, Inc.
| 2023-08-16 | Sale | CARLSON CAPITAL L P | 10 percent owner | 1,000 0.0029% | $0.39 | $392 | -27.03% | |
| 2023-08-15 | Sale | CARLSON CAPITAL L P | 10 percent owner | 215,000 0.6319% | $0.44 | $94,041 | -33.85% | |
| 2023-08-15 | Weisman Harlan F | President and CEO | 600,000 1.0079% | $0.25 | $150,000 | -33.85% | ||
| 2023-08-15 | Mikhak Zamaneh | Chief Medical Officer | 120,000 0.2016% | $0.25 | $30,000 | -33.85% | ||
| 2023-08-15 | MILLS ROBERT S | director | 40,000 0.0672% | $0.25 | $10,000 | -33.85% | ||
| 2023-08-15 | ROCAMBOLI STEPHEN | director | 20,000 0.0336% | $0.25 | $5,000 | -33.85% | ||
| 2023-08-15 | COLEMAN KIRK ALLEN | Chief Financial Officer | 20,000 0.0336% | $0.25 | $5,000 | -33.85% | ||
| 2023-08-15 | Roberts Brandi | director | 20,000 0.0336% | $0.25 | $5,000 | -33.85% | ||
| 2023-03-10 | Weisman Harlan F | President and CEO | 150,000 0.5044% | $0.88 | $131,835 | -50.14% | ||
| 2023-03-10 | ROCAMBOLI STEPHEN | director | 13,000 0.0399% | $0.80 | $10,433 | -50.14% | ||
| 2023-03-10 | COLEMAN KIRK ALLEN | Chief Financial Officer | 12,000 0.0362% | $0.79 | $9,457 | -50.14% | ||
| 2023-03-10 | Mikhak Zamaneh | Chief Medical Officer | 15,000 0.0471% | $0.82 | $12,300 | -50.14% | ||
| 2022-12-15 | Weisman Harlan F | President and CEO | 50,000 0.1733% | $1.06 | $53,000 | -54.90% | ||
| 2022-11-22 | Fletcher Aaron G.L. | director | 43,470 0.1158% | $1.15 | $49,991 | -61.81% | ||
| 2022-09-29 | Sale | THURMAN RANDY H | 40,255 0.1589% | $4.29 | $172,694 | -83.95% | ||
| 2022-05-18 | Weisman Harlan F | 4,615 0.02% | $5.50 | $25,383 | -72.95% | |||
| 2022-05-16 | Fletcher Aaron G.L. | 24,600 0.1035% | $5.08 | $124,968 | -69.75% | |||
| 2022-05-16 | Mattes Glenn R. | President and CEO | 16,000 0.0633% | $4.78 | $76,480 | -69.75% | ||
| 2022-05-16 | ROCAMBOLI STEPHEN | 3,000 0.0113% | $4.54 | $13,620 | -69.75% | |||
| 2022-05-16 | Weisman Harlan F | 2,500 0.0098% | $4.74 | $11,850 | -69.75% |
Insider Historical Profitability
| CARLSON CAPITAL L P | 10 percent owner | 5064000 201.0146% | $1.73 | 0 | 2 | |
| Weisman Harlan F | President and CEO | 814615 32.336% | $1.73 | 6 | 0 | <0.0001% |
| Mikhak Zamaneh | Chief Medical Officer | 135000 5.3588% | $1.73 | 2 | 0 | <0.0001% |
| MILLS ROBERT S | director | 55980 2.2221% | $1.73 | 2 | 4 | |
| ROCAMBOLI STEPHEN | director | 36000 1.429% | $1.73 | 3 | 3 | <0.0001% |
| COLEMAN KIRK ALLEN | Chief Financial Officer | 35675 1.4161% | $1.73 | 5 | 5 | <0.0001% |
| Roberts Brandi | director | 20000 0.7939% | $1.73 | 1 | 0 | |
| Lung Therapeutics, Inc. | 10 percent owner | 2235000 88.7179% | $1.73 | 0 | 2 | |
| Fletcher Aaron G.L. | director | 143470 5.695% | $1.73 | 10 | 0 | +98.86% |
| Mattes Glenn R. | President and CEO | 36000 1.429% | $1.73 | 3 | 6 | <0.0001% |
| Fairbairn Malcolm | director | 10000 0.3969% | $1.73 | 1 | 2 | <0.0001% |
| WINDSOR JAMES BRIAN | Chief Science Officer | 5000 0.1985% | $1.73 | 1 | 1 | |
| THURMAN RANDY H | 0 0% | $1.73 | 2 | 3 | <0.0001% |
Institutional Investor Ownership
No records found… | |||||||